|
1
|
Noronha IL, Fujihara CK and Zatz R: The
inflammatory component in progressive renal disease - are
interventions possible? Nephrol Dial Transplant. 17:363–368. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wynn TA: Cellular and molecular mechanisms
of fibrosis. J Pathol. 214:199–210. 2008. View Article : Google Scholar
|
|
3
|
Neilson EG: Mechanisms of disease:
Fibroblasts - a new look at an old problem. Nat Clin Pract Nephrol.
2:101–108. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boor P, Ostendorf T and Floege J: Renal
fibrosis: novel insights into mechanisms and therapeutic targets.
Nat Rev Nephrol. 6:643–656. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu Y: Renal fibrosis: new insights into
the pathogenesis and therapeutics. Kidney Int. 69:213–217. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eddy AA: Molecular basis of renal
fibrosis. Pediatr Nephrol. 15:290–301. 2000. View Article : Google Scholar
|
|
7
|
Böttinger EP and Bitzer M: TGF-beta
signaling in renal disease. J Am Soc Nephrol. 13:2600–2610.
2002.
|
|
8
|
Fujihara CK, Malheiros DM, Zatz R and
Noronha IL: Mycophenolate mofetil attenuates renal injury in the
rat remnant kidney. Kidney Int. 54:1510–1519. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lewis EJ, Hunsicker LG, Clarke WR, et al;
Collaborative Study Group. Renoprotective effect of the
angiotensin-receptor antagonist irbesartan in patients with
nephropathy due to type 2 diabetes. N Engl J Med. 345:851–860.
2001. View Article : Google Scholar
|
|
10
|
Brenner BM, Cooper ME, de Zeeuw D, et al;
RENAAL Study Investigators. Effects of losartan on renal and
cardiovascular outcomes in patients with type 2 diabetes and
nephropathy. N Engl J Med. 345:861–869. 2001. View Article : Google Scholar
|
|
11
|
Chang HK, Yang HY, Lee TH, et al:
Armeniacae semen extract suppresses lipopolysaccharide-induced
expressions of cyclooxygenase (correction of cycloosygenase)-2 and
inducible nitric oxide synthase in mouse BV2 microglial cells. Biol
Pharm Bull. 28:449–454. 2005. View Article : Google Scholar
|
|
12
|
Fukuda T, Ito H, Mukainaka T, Tokuda H,
Nishino H and Yoshida T: Anti-tumor promoting effect of glycosides
from Prunus persica seeds. Biol Pharm Bull. 26:271–273.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu N, Tolbert E, Pang M, Ponnusamy M, Yan
H and Zhuang S: Suramin inhibits renal fibrosis in chronic kidney
disease. J Am Soc Nephrol. 22:1064–1075. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Robertson H, Ali S, McDonnell BJ, Burt AD
and Kirby JA: Chronic renal allograft dysfunction: the role of T
cell-mediated tubular epithelial to mesenchymal cell transition. J
Am Soc Nephrol. 15:390–397. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chang HK, Shin MS, Yang HY, et al:
Amygdalin induces apoptosis through regulation of Bax and Bcl-2
expressions in human DU145 and LNCaP prostate cancer cells. Biol
Pharm Bull. 29:1597–1602. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vongwiwatana A, Tasanarong A, Rayner DC,
Melk A and Halloran PF: Epithelial to mesenchymal transition during
late deterioration of human kidney transplants: the role of tubular
cells in fibrogenesis. Am J Transplant. 5:1367–1374. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zeisberg M, Hanai J, Sugimoto H, et al:
BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal
transition and reverses chronic renal injury. Nat Med. 9:964–968.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang W, Huang XR, Li AG, et al: Signaling
mechanism of TGF-beta1 in prevention of renal inflammation: role of
Smad7. J Am Soc Nephrol. 16:1371–1383. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shihab FS, Bennett WM, Yi H and Andoh TF:
Pirfenidone treatment decreases transforming growth factor-beta1
and matrix proteins and ameliorates fibrosis in chronic
cyclosporine nephrotoxicity. Am J Transplant. 2:111–119. 2002.
View Article : Google Scholar
|
|
20
|
Liu Y: Epithelial to mesenchymal
transition in renal fibrogenesis: pathologic significance,
molecular mechanism, and therapeutic intervention. J Am Soc
Nephrol. 15:1–12. 2004. View Article : Google Scholar
|
|
21
|
Heeg MH, Koziolek MJ, Vasko R, et al: The
antifibrotic effects of relaxin in human renal fibroblasts are
mediated in part by inhibition of the Smad2 pathway. Kidney Int.
68:96–109. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Satoh S, Yamaguchi T, Hitomi A, et al:
Fasudil attenuates interstitial fibrosis in rat kidneys with
unilateral ureteral obstruction. Eur J Pharmacol. 455:169–174.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Strutz F and Müller GA: Renal fibrosis and
the origin of the renal fibroblast. Nephrol Dial Transplant.
21:3368–3370. 2006. View Article : Google Scholar : PubMed/NCBI
|
